3 References 16. Mitchell AC. Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliat Med. 1999; 13: 427– 428 doi: 10.1191/026921699667559279. 17. Niesters M, Dahan A, Swartjes M, Noppers I, Fillingim RB, Aarts L, al. et. Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain. 2011; 152: 656–663 doi: 10.1016/j.pain.2010.12.015. 18. Schmidt AP, Tort ABL, Silveira PP, B¨ohmer AE, Hansel G, Knorr L, al. et. The NMDA antagonist MK-801 induces hyperalgesia and increases CSF excitatory amino acids in rats: reversal by guanosine. Pharmacol Biochem Behav. 2009; 91: 549–553 doi: 10.1016/j.pbb.2008.09.009. 19. Bonaventura J, Gomez JL, Carltom ML, Lam S, Sanchez-Soto M, Morris PJ, al. et. Target deconvolution studies of (2R,6R)-dehydroxynorketamine: an elusive search. Mol Psychiatry. 2022; doi: 10.1038/s41380-022-01673-w. 20. Olofsen E, Kamp J, Henthorn TK, Velzen M van, Niesters M, Sarton E, al. et. Ketamine psychedelic and analgesic effects are connected. Anesthesiology. 2022; 136: 792–801 doi: 10.1097/ALN.0000000000004176. 21. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: Evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992; 260: 1209–1213 . 22. Gitlin J, Chamadia S, Locascio JJ, Ethridge BR, Pedemonte JC, Hahm EY, al. et. Dissociative and analgesic properties of ketamine are independent. Anesthesiology. 2020; 133: 1021–1028 doi: 10.1097/ALN.0000000000003529. 63
RkJQdWJsaXNoZXIy MTk4NDMw